Table 1.
Characteristics of included trials (two-armed parallel group).
| Author | Number of patients | Intervention | ||||
|---|---|---|---|---|---|---|
| Experimental | Control | Experimental | Control | Duration (wks) | Outcomes | |
| Liu and Hu 2008 [12] | 30 | 30 | LM, Ber, Met | LM + Met | 8 | FBG, PPG, HbA1c, FINS |
| Li 2008 [32] | 33 | 32 | LM, Ber | LM + Met | 12 | FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C |
| Wang 2008 [14] | 30 | 31 | LM, Ber | LM | 12 | FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C, AE |
| Zhang et al. 2008 [9] | 58 | 52 | LM, Ber | Placebo, LM | 12 | FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C, AE |
| Yin et al. 2008 [10] | 15 | 16 | LM, Ber | Met, LM | 13 | FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C, AE |
| Sheng and Xie 2010 [15] | 30 | 30 | Ber, Met, Glip | Met, Glip | 12 | FBG, FINS, AE |
| Ye 2010 [16] | 40 | 40 | Ber, Met, Glim | Met, Glim | 12 | FBG, PPG, HbA1c, TC, TG, LDL-C, HDL-C, AE |
| Zhang et al. 2011 [17] | 30 | 30 | LM, Ber | LM, Ber, Ros | 12 | FBG, HbA1c, TC, TG, LDL-C, HDL-C |
| Yin et al. 2011 [18] | 30 | 30 | LM, Ber, Met | LM, Met | 24 | FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C, AE |
Note: AE: adverse effect; Ber: berberine; Glim: glimepiride; Glip: glipizide; LM: lifestyle modification; Met: metformin; Ros: rosiglitazone.